← Back to directory

Markus F. Neurath

Researcher Next ID · RN-026401

Researcher · Biochemistry, Genetics and Molecular Biology

Friedrich-Alexander-Universität Erlangen-Nürnberg

Erlangen, Germany

Not currently recruitingFunding unknown
Works count
1,492
Citation count
84,608
H-index
144
i10-index
709

Research interests

Biochemistry, Genetics and Molecular Biology
Medicine
Immunology and Microbiology
Inflammatory Bowel Disease
Microscopic Colitis
Immune Cell Function and Interaction
Helicobacter pylori-related gastroenterology studies
Esophageal Cancer Research and Treatment

Publications

  • IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

    Nature Reviews Gastroenterology & Hepatology · 2023 · https://doi.org/10.1038/s41575-023-00768-1

  • Vascular occlusion by neutrophil extracellular traps in COVID-19

    EBioMedicine · 2020 · 10.1016/j.ebiom.2020.102925

  • Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

    Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.04.002

  • Targeting immune cell circuits and trafficking in inflammatory bowel disease

    Nature Immunology · 2019 · 10.1038/s41590-019-0415-0

  • Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

    ˜The œLancet. Gastroenterology & hepatology · 2018 · https://doi.org/10.1016/s2468-1253(18)30233-4

  • Environmental triggers in IBD: a review of progress and evidence

    Nature Reviews Gastroenterology & Hepatology · 2017 · https://doi.org/10.1038/nrgastro.2017.136

  • Chemically induced mouse models of acute and chronic intestinal inflammation

    Nature Protocols · 2017 · https://doi.org/10.1038/nprot.2017.044

  • Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells

    Nature Medicine · 2017 · https://doi.org/10.1038/nm.4373

  • Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

    The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)30570-6

  • Mend Your Fences

    Cellular and Molecular Gastroenterology and Hepatology · 2017 · 10.1016/j.jcmgh.2017.03.007

  • Current and emerging therapeutic targets for IBD

    Nature Reviews Gastroenterology & Hepatology · 2017 · 10.1038/nrgastro.2016.208

  • IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases

    Nature · 2014 · 10.1038/nature12979

  • Cytokines in inflammatory bowel disease

    Nature reviews. Immunology · 2014 · https://doi.org/10.1038/nri3661

  • Mucosal healing in inflammatory bowel diseases: a systematic review

    Gut · 2012 · 10.1136/gutjnl-2012-302830

  • Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis

    Nature · 2011 · https://doi.org/10.1038/nature10400

  • Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice

    The Journal of Experimental Medicine · 2010 · https://doi.org/10.1084/jem.20092366

  • STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing

    The Journal of Experimental Medicine · 2009 · 10.1084/jem.20082683

  • NF‐κB in inflammatory bowel disease

    Journal of Internal Medicine · 2008 · 10.1111/j.1365-2796.2008.01953.x

  • Epithelial NEMO links innate immunity to chronic intestinal inflammation

    Nature · 2007 · https://doi.org/10.1038/nature05698

  • An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression

    Nature Protocols · 2007 · 10.1038/nprot.2007.279

  • Chemically induced mouse models of intestinal inflammation

    Nature Protocols · 2007 · https://doi.org/10.1038/nprot.2007.41

  • Anti–Interleukin-12 Antibody for Active Crohn's Disease

    New England Journal of Medicine · 2004 · 10.1056/nejmoa033402

  • TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling

    Immunity · 2004 · 10.1016/j.immuni.2004.07.020

  • Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7

    The Journal of Immunology · 2004 · 10.4049/jimmunol.172.9.5149

  • Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo

    Gastroenterology · 2004 · 10.1053/j.gastro.2004.06.050

  • CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

    Journal of Clinical Investigation · 2003 · 10.1172/jci16432

  • Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis

    Gastroenterology · 2003 · 10.1053/gast.2003.50146

  • Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet

    Science · 2002 · 10.1126/science.1065544

  • Soluble gp130 is the natural inhibitor of soluble interleukin‐6 receptor transsignaling responses

    European Journal of Biochemistry · 2001 · 10.1046/j.1432-1327.2001.01867.x

  • Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo

    Nature Medicine · 2000 · https://doi.org/10.1038/75068

  • Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5

    The Journal of Immunology · 1996 · https://doi.org/10.4049/jimmunol.157.3.1261

  • Local administration of antisense phosphorothiate olignucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in mice

    Nature Medicine · 1996 · 10.1038/nm0996-998

Current projects

    No projects listed.